Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers.

Filip JankuDivya SakamuriShumei KatoHelen J HuangS Greg CallAung NaingVeronica R HolleySapna Pradyuman PatelRodabe N AmariaGerald S FalchookSarina A Piha-PaulRalph G ZinnerApostolia-Maria TsimberidouDavid S HongFunda Meric-Bernstam

Published in: Cancer (2020)

Vemurafenib combined with sorafenib or crizotinib was well tolerated with encouraging activity, including among patients who previously received treatment with BRAF, MEK, or ERK inhibitors.

Keyphrases

wild type
advanced non small cell lung cancer
pi k akt
signaling pathway
metastatic colorectal cancer
cell proliferation
open label
randomized controlled trial
young adults
double blind
childhood cancer